Clinical Edge Journal Scan

Triglyceride-glucose index: A promising atherosclerotic marker in PsA


 

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs without CA (8.82 vs 8.54; P = .002) or CAP (8.88 vs 8.55; P = .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Recommended Reading

JAKi effective for PsA but higher doses may have increased toxicity
Psoriatic Arthritis ICYMI
Real world study finds no evidence of increased cancer risk with JAKi vs TNFi in PsA
Psoriatic Arthritis ICYMI
Ultrasound helps screen patients with moderate-to-severe psoriasis progressing to subclinical PsA
Psoriatic Arthritis ICYMI
Concurrent onset of skin and joint symptoms tied to high disease activity in PsA
Psoriatic Arthritis ICYMI
Apremilast safe and effective in biologic-naive patients with early PsA
Psoriatic Arthritis ICYMI
Disease burden is higher in women vs men with psoriatic arthritis
Psoriatic Arthritis ICYMI
Commentary: Disease activity, JAK inhibitors, and pregnancy risks in PsA, April 2023
Psoriatic Arthritis ICYMI
Does COVID-19 vaccination worsen disease activity in PsA patients on targeted therapy?
Psoriatic Arthritis ICYMI
Sex-based differences in efficacy and safety of tofacitinib in PsA
Psoriatic Arthritis ICYMI
Real-life study confirms benefits of secukinumab in PsA
Psoriatic Arthritis ICYMI